$APRE
Aprea Therapeutics, Inc.

2024 Q4 Form 10-Q Financial Statement

#000155837024014767 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $354.6K
YoY Change 10.82%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.605M
YoY Change -6.67%
% of Gross Profit
Research & Development $2.846M
YoY Change 34.1%
% of Gross Profit
Depreciation & Amortization $5.430K
YoY Change
% of Gross Profit
Operating Expenses $4.452M
YoY Change 15.86%
Operating Profit -$4.097M
YoY Change 16.3%
Interest Expense $348.7K
YoY Change 8.57%
% of Operating Profit
Other Income/Expense, Net $313.2K
YoY Change -1.6%
Pretax Income -$3.784M
YoY Change 18.24%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$3.784M
YoY Change 18.08%
Net Earnings / Revenue -1066.99%
Basic Earnings Per Share -$0.64
Diluted Earnings Per Share -$0.64
COMMON SHARES
Basic Shares Outstanding 5.435M 5.432M
Diluted Shares Outstanding 5.940M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $26.25M
YoY Change 3.35%
Cash & Equivalents $26.20M
Short-Term Investments
Other Short-Term Assets $234.2K
YoY Change -21.93%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $26.48M
YoY Change 3.29%
LONG-TERM ASSETS
Property, Plant & Equipment $86.95K
YoY Change 0.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $281.7K
YoY Change
Total Long-Term Assets $410.1K
YoY Change 223.85%
TOTAL ASSETS
Total Short-Term Assets $26.48M
Total Long-Term Assets $410.1K
Total Assets $26.89M
YoY Change 4.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.154M
YoY Change 33.78%
Accrued Expenses $2.482M
YoY Change -24.79%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.636M
YoY Change -12.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.636M
Total Long-Term Liabilities $0.00
Total Liabilities $3.636M
YoY Change -13.43%
SHAREHOLDERS EQUITY
Retained Earnings -$318.1M
YoY Change 4.43%
Common Stock $5.435K
YoY Change 45.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.95M
YoY Change
Total Liabilities & Shareholders Equity $26.89M
YoY Change 4.38%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$3.784M
YoY Change 18.08%
Depreciation, Depletion And Amortization $5.430K
YoY Change
Cash From Operating Activities -$2.468M
YoY Change 10.19%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.160K
YoY Change
NET CHANGE
Cash From Operating Activities -2.468M
Cash From Investing Activities 0.000
Cash From Financing Activities -1.160K
Net Change In Cash -2.469M
YoY Change 5.99%
FREE CASH FLOW
Cash From Operating Activities -$2.468M
Capital Expenditures $0.00
Free Cash Flow -$2.468M
YoY Change 5.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001781983
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5434903
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3736673
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
apre Lessee Operating Lease Annual Base Rent Obligation After Current Year
LesseeOperatingLeaseAnnualBaseRentObligationAfterCurrentYear
0
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39069
dei Entity Registrant Name
EntityRegistrantName
Aprea Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-2246769
dei Entity Address Address Line1
EntityAddressAddressLine1
3805 Old Easton Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Doylestown
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
18902
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
463-9385
dei Security12b Title
Security12bTitle
Common stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
APRE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5434903
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26249625
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21606820
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
234195
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
914275
CY2024Q3 us-gaap Assets Current
AssetsCurrent
26483820
CY2023Q4 us-gaap Assets Current
AssetsCurrent
22521095
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
86950
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
88362
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
41537
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
40717
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
281662
CY2024Q3 us-gaap Assets
Assets
26893969
CY2023Q4 us-gaap Assets
Assets
22650174
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1153880
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1670369
CY2024Q3 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2482008
CY2023Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2186262
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
528974
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
3635888
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4385605
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5434903
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3736673
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
5435
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
3736
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
350693403
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
335644204
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10604747
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-10611273
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-318147073
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-308083161
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
21947018
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
16953506
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26893969
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22650174
CY2024Q3 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
354621
CY2023Q3 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
319468
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
1296764
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
569156
CY2024Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2846399
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2122603
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7004451
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5581802
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1605238
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1719715
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5385923
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6784388
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
4451637
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
3842318
us-gaap Operating Expenses
OperatingExpenses
12390374
us-gaap Operating Expenses
OperatingExpenses
12366190
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4097016
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3522850
us-gaap Operating Income Loss
OperatingIncomeLoss
-11093610
us-gaap Operating Income Loss
OperatingIncomeLoss
-11797034
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
348741
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
321215
us-gaap Operating Income Loss
OperatingIncomeLoss
-11797034
CY2024Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
348741
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
321215
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1014518
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
913846
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-35494
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2880
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
15180
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
39686
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
313247
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
318335
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1029698
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
953532
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3783769
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3204515
us-gaap Net Income Loss
NetIncomeLoss
-10063912
us-gaap Net Income Loss
NetIncomeLoss
-10843502
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
23557
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1002
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6526
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12466
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3760212
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3205517
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10057386
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10855968
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.86
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.03
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5939755
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5939755
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3735176
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3735176
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5360579
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5360579
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3577482
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3577482
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
25643678
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4871865
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16244
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
61956
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4379890
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
26481978
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
269323
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-73420
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3259097
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1014518
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
913846
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-35494
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2880
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
15180
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
39686
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
313247
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
318335
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1029698
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
953532
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3783769
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3204515
us-gaap Net Income Loss
NetIncomeLoss
-10063912
us-gaap Net Income Loss
NetIncomeLoss
-10843502
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
23557
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1002
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
6526
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-12466
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3760212
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3205517
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10057386
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10855968
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.86
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.86
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.03
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5939755
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5939755
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3735176
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3735176
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5360579
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5360579
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3577482
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3577482
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
25643678
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4871865
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
16244
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
61956
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4379890
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
26481978
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
269323
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-73420
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3259097
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
23418784
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
76031
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
23418784
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
76031
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1002
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3204515
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
20289298
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
16953506
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14709705
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
85830
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15083
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2810091
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
28923867
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
21060
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
128488
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1948
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3470052
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
25559295
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1155
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
149090
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
23557
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3783769
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
21947018
us-gaap Profit Loss
ProfitLoss
-10063912
us-gaap Profit Loss
ProfitLoss
-10843502
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
16890
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2066
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
363408
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
361598
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
15180
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
39686
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-398531
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1077138
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-515964
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
21873
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
299387
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
982563
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-528974
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10045814
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8437950
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
15478
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
85943
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15478
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-85943
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15999598
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5788918
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1312108
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
648928
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14687490
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5139990
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
4626198
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1002
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-3204515
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
20289298
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
16953506
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
14709705
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
85830
CY2024Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-15083
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-2810091
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
28923867
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
21060
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
128488
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1948
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3470052
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
25559295
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1155
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
149090
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
23557
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-3783769
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
21947018
us-gaap Profit Loss
ProfitLoss
-10063912
us-gaap Profit Loss
ProfitLoss
-10843502
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
16890
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2066
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
363408
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
361598
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
15180
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
39686
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-398531
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1077138
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-515964
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
21873
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
299387
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
982563
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-528974
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10045814
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8437950
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15478
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-85943
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
15999598
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5788918
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1312108
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
648928
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14687490
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5139990
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
4626198
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3383903
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17427
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-8782
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21647537
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-3383903
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17427
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-8782
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21647537
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28786647
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26291162
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25393962
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26249625
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25353513
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
41537
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
40449
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26291162
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25393962
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b>—The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant items subject to such estimates and assumptions, are used for, but not limited to, include stock-based compensation and accounting for research and development costs.</p>
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28786647
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26291162
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25393962
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26249625
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25353513
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
41537
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
40449
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26291162
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25393962
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Use of estimates</b>—The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates. Significant items subject to such estimates and assumptions, are used for, but not limited to, include stock-based compensation and accounting for research and development costs.</p>
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
41537
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
40717
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
41537
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
40717
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2993473
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
634623
CY2024Q3 apre Lessee Operating Lease Number Of Operating Leases
LesseeOperatingLeaseNumberOfOperatingLeases
1
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
19998
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
19998
us-gaap Operating Lease Expense
OperatingLeaseExpense
59993
us-gaap Operating Lease Expense
OperatingLeaseExpense
59993
apre Lessee Operating Lease Annual Base Rent
LesseeOperatingLeaseAnnualBaseRent
110000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2993473
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
634623
CY2024Q3 apre Lessee Operating Lease Number Of Operating Leases
LesseeOperatingLeaseNumberOfOperatingLeases
1
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
19998
CY2024Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
19998
us-gaap Operating Lease Expense
OperatingLeaseExpense
59993
us-gaap Operating Lease Expense
OperatingLeaseExpense
59993
apre Lessee Operating Lease Annual Base Rent
LesseeOperatingLeaseAnnualBaseRent
110000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
168225
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
138601
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
168225
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
138601
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
673322
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1016960
CY2024Q3 apre Research And Development Related Liabilities Current
ResearchAndDevelopmentRelatedLiabilitiesCurrent
1582173
CY2023Q4 apre Research And Development Related Liabilities Current
ResearchAndDevelopmentRelatedLiabilitiesCurrent
856575
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
58288
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
174126
CY2024Q3 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2482008
CY2023Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2186262
CY2024Q3 apre Stock Shares Authorized
StockSharesAuthorized
440000000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Convertible Shares Issuable
PreferredStockConvertibleSharesIssuable
28112
apre Common Stock Number Of Voting Rights Per Share
CommonStockNumberOfVotingRightsPerShare
1
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
149090
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
76031
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
363408
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
361598
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q3 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
100000
CY2023Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
100000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1016960
CY2024Q3 apre Research And Development Related Liabilities Current
ResearchAndDevelopmentRelatedLiabilitiesCurrent
1582173
CY2023Q4 apre Research And Development Related Liabilities Current
ResearchAndDevelopmentRelatedLiabilitiesCurrent
856575
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
58288
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
174126
CY2024Q3 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2482008
CY2023Q4 apre Accrued Liabilities And Employee Related Liabilities Current
AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
2186262
CY2024Q3 apre Stock Shares Authorized
StockSharesAuthorized
440000000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
40000000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Convertible Shares Issuable
PreferredStockConvertibleSharesIssuable
28112
apre Common Stock Number Of Voting Rights Per Share
CommonStockNumberOfVotingRightsPerShare
1
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
149090
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
76031
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
363408
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
361598
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q3 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
100000
CY2023Q4 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
100000
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0

Files In Submission

Name View Source Status
0001558370-24-014767-index-headers.html Edgar Link pending
0001558370-24-014767-index.html Edgar Link pending
0001558370-24-014767.txt Edgar Link pending
0001558370-24-014767-xbrl.zip Edgar Link pending
apre-20240930.xsd Edgar Link pending
apre-20240930x10q.htm Edgar Link pending
apre-20240930xex10d1.htm Edgar Link pending
apre-20240930xex31d1.htm Edgar Link pending
apre-20240930xex31d2.htm Edgar Link pending
apre-20240930xex32d1.htm Edgar Link pending
apre-20240930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
apre-20240930_def.xml Edgar Link unprocessable
apre-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
apre-20240930_cal.xml Edgar Link unprocessable
apre-20240930_lab.xml Edgar Link unprocessable
apre-20240930x10q_htm.xml Edgar Link completed